The -c(=x)- Is Part Of A -c(=x)x- Group, Wherein The X's May Be The Same Or Diverse Chalcogens Patents (Class 558/172)
-
Patent number: 9295747Abstract: Provided are a contact lens care preparation capable of imparting durable surface lubricity and amebic adhesion inhibitory effect to a contact lens surface through a simple treatment, and a contact lens packaging solution utilizing the same. The contact lens care preparation is composed of a solution containing 0.01 to 2 weight/volume % of a polymer having particular monomer units with a phosphorylcholine-like group, particular (meth)acrylamide derivative units, and particular monomer units with a hydrophobic group at a particular ratio, and a weight average molecular weight of 5,000 to 2,000,000, and is useful as a contact lens packaging solution.Type: GrantFiled: March 2, 2012Date of Patent: March 29, 2016Assignee: NOF CORPORATIONInventors: Yosuke Matsuoka, Norio Iwakiri, Mao Maruhashi, Nobuyuki Sakamoto
-
Patent number: 8999323Abstract: The present invention relates to a polymerization-curable composition for the preparation of biodegradable, biocompatible, cross-linked polymers on the basis of polyvinyl alcohol comprising: 5 to 100% by weight of (a) vinyl ester monomer(s) of one of the general formulas (I) to (III): wherein X is oxygen, sulfur, nitrogen, or phosphorus; n is 1 to 1000, at least 20% of the n being ?2; the R1 are selected from hydrogen; straight, branched or cyclic, saturated or unsaturated, n-valent hydrocarbon groups having 1 to 30 carbon atoms, which optionally have heteroatoms and are optionally substituted with one or more substituents selected from —OH, —COON, —CN, —CHO, and ?O, and n-valent radicals of biodegradable, biocompatible oligomers and polymers; m is an integer from 1 to 5; the R2 are selected from hydrogen, —OH, ?O, and the options listed for R1; and the R3 are selected from hydrogen, —OH, and the options listed for R1; 0 to 50% by weight of ethylenically unsaturated co-monomers; 0 to 10% by weight of (a)Type: GrantFiled: November 21, 2008Date of Patent: April 7, 2015Assignee: Technische Universität WienInventors: Robert Liska, Jürgen Stampfl, Franz Varga, Heinrich Gruber, Stefan Baudis, Christian Heller, Monika Schuster, Helga Bergmeister, Günter Weigel, Claudia Dworak
-
Patent number: 8987504Abstract: The invention relates to a process for the aminohydroxylation of alkenes using N-oxycarbamate reagents, e.g. N-acyloxycarbamate, N-alkyloxycarbonyloxycarbamate and N-aralkoxycarbonyloxycarbamate reagents. The invention particularly relates to an intermolecular aminohydroxylation reaction that can be carried out in the absence of added base. The invention also relates to novel N-oxycarbamate reagents that are stable crystalline materials. The process of the invention is useful in the synthesis of compounds having a vicinal amino alcohol moiety, such as biologically active compounds.Type: GrantFiled: June 20, 2011Date of Patent: March 24, 2015Assignee: Victoria Link LimitedInventors: Simon Peter Harold Mee, Andreas Luxenburger, Lawrence Daniel Harris
-
Publication number: 20150064788Abstract: The present invention relates to a method for transducing a target cell, the method comprising the step of contacting a target cell with a retroviral vector and a poloxamer having a molecular weight of 12.8 kDa to about 15 kDa. Further, the invention relates to the use of a poloxamer as defined herein, optionally in combination with a polycationic substance as defined herein, for transducing a target cell with a retroviral vector and a kit comprising a retroviral vector, a poloxamer as defined herein and, optionally, instructions for use.Type: ApplicationFiled: February 28, 2013Publication date: March 5, 2015Inventors: Natasa Anastasov, Ines Höfig, Christian Thirion
-
Publication number: 20150065462Abstract: Conjugates of drugs suitable for use in the treatment of inflammatory bowel disease and phospholipids, and their use in the treatment of inflammatory bowel disease, are disclosed. The disclosed conjugates serve as targeted prodrugs which are suitable for oral administration, and which are capable of releasing the drug selectively at the diseased tissue upon activation by PLA2.Type: ApplicationFiled: November 10, 2014Publication date: March 5, 2015Inventor: Arik DAHAN
-
Patent number: 8940907Abstract: The present invention relates to a process for the preparation of phosphoric esters, and to selected compounds.Type: GrantFiled: October 8, 2010Date of Patent: January 27, 2015Assignee: Merck Patent GmbHInventor: Karl Heinz Gluesenkamp
-
Publication number: 20140378529Abstract: Methods for treating a subject determined to have a cancer comprising a heterozygous inactivation of a housekeeping gene (or a homozygous deletion of a functionally redundant housekeeping gene) by treating the subject with an inhibitor of the gene. For example, a subject having a cancer with an ENO gene deletion can be treated with a glycolysis inhibitor, such as an enolase inhibitor. In some aspects, a subject having a cancer with an ARS gene deletion can be treated with an ARS inhibitor.Type: ApplicationFiled: December 14, 2012Publication date: December 25, 2014Applicants: DANA-FARBER CANCER INSTITUTE, INC., BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Florian L. Muller, Eliot Fletcher-Sananikone, Simona Colla, Elisa Aquilanti, Ronald DePinho
-
Patent number: 8853429Abstract: There is provides a process for the preparation of a compound of formula (7): wherein R is an optionally substituted hydrocarbyl group or an optionally substituted heterocyclic group; provides that R is not a compound of Formula (a): wherein Ra represents an alkyl group, such as a C1-16 alkyl group, and preferably an isopropyl group; Rb represents an aryl group, preferably a 4-fluorophenyl group; Rc represents hydrogen, a protecting group or an alkyl group, such as a C1-16 alkyl group, and preferably a methyl group; and Rd represents hydrogen, a protecting group or a SO2Re group where Re is an alkyl group, such as a C1-16 alkyl group, and preferably a methyl group.Type: GrantFiled: July 26, 2013Date of Patent: October 7, 2014Assignee: Redx Pharma LimitedInventors: David John Moody, Jonathan William Wiffen
-
Publication number: 20140296187Abstract: A method for preparing plasmalogens and derivatives thereof represented by Formula B, wherein R1 and R2 are similar or different, derived from fatty acids; R3 is selected from hydrogen and small alkyl groups. The synthetic route involves production of novel cyclic plasmalogen precursors of Formula A and their conversion to plasmalogens and plasmalogen derivatives of Formula B. Also disclosed is the therapeutic use of plasmalogens and derivatives thereof as produced by the synthetic route of the present invention.Type: ApplicationFiled: November 16, 2012Publication date: October 2, 2014Inventors: M. Amin Khan, Paul L. Wood, Dayan Goodenowe
-
Publication number: 20140243391Abstract: The invention relates to novel compounds, in particular novel O-substituted phospholipids that are useful for the in vitro and in vivo delivery of drugs as well as nucleic acids into cells. The invention also relates to pharmaceutical compositions and supramolecular complexes comprising said compounds and the use of these compounds in therapeutic treatment, in particular in gene therapy.Type: ApplicationFiled: July 20, 2012Publication date: August 28, 2014Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE STRASBOURGInventors: Luc Lebeau, Philippe Pierrat, Francoise Pons, Guy Zuber
-
Publication number: 20140234774Abstract: The present application relates to a photoactive compound including an oxime ester group and a phosphonate group together, and a photosensitive resin composition comprising the same, the compound of the present application having excellent storage stability and high-temperature process characteristics.Type: ApplicationFiled: May 22, 2013Publication date: August 21, 2014Inventors: Changho Cho, Sunghyun Kim, Han Soo Kim, Sunhwa Kim, Raisa Kharbash, Jongho Park
-
Publication number: 20140161839Abstract: The present invention relates to a compound of the following general formula (I): R1—NH—CH(R2)—P(?O)(OR3)—CH2—C(R4)(R5)—CONH—CH(R6)—COOR7 (I) or a pharmaceutically acceptable salt of the latter, an isomer or a mixture of isomers in any proportions, especially a mixture of enantiomers, and in particular a racemic mixture, for which R1 represents a —C(?O)—O—C(R8)(R9)—OC(?O)—R10 group; R2 represents an optionally substituted hydrocarbon-based chain, an aryl or heteroaryl group or a methylene group substituted by a heterocycle; R3 represents a hydrogen atom or a —C(R12)(R13)—OC(?O)—R14 group; R4 and R5 form, together with the carbon that bears them, a saturated hydrocarbon-based ring or an optionally substituted piperidine ring or R4 represents a hydrogen atom and R5 represents a phenyl or a benzyl that is optionally substituted, a heteroaromatic ring or a methylene group substituted by a heterocycle; R6 represents an optionally substituted hydrocarbon-based chain or a phenyl or a benzyl that is optionally substiType: ApplicationFiled: February 18, 2014Publication date: June 12, 2014Applicant: PHARMALEADSInventors: Bernard Roques, Herve Poras, Marie-Claude Fournie-Zaluski
-
Patent number: 8680314Abstract: Provided are amino group-containing phosphorylcholine compound and a method for production thereof, that has a highly active amino group efficiently reactive with a wide variety of functional groups and the like under mild conditions, and is capable of introducing a phosphorylcholine-like group to various substrate surfaces to provide functionalities of the group. The amino group-containing phosphorylcholine compound of the present invention is represented by at least one of formulae (1) and (1?), and may be used as a compound, or a material thereof, capable of introducing a phosphorylcholine-like group to the surface of various substrates, such as medical instruments, cosmetics materials, and medicinal substances.Type: GrantFiled: December 22, 2011Date of Patent: March 25, 2014Assignee: NOF CorporationInventors: Nobuyuki Yoshioka, Nobuyuki Sakamoto, Yosuke Matsuoka, Norio Iwakiri
-
Publication number: 20130274479Abstract: The invention relates to a process for the aminohydroxylation of alkenes using N-oxycarbamate reagents, e.g. N-acyloxycarbamate, N-alkyloxycarbonyloxycarbamate and N-aralkoxycarbonyloxycarbamate reagents. The invention particularly relates to an intermolecular aminohydroxylation reaction that can be carried out in the absence of added base. The invention also relates to novel N-oxycarbamate reagents that are stable crystalline materials. The process of the invention is useful in the synthesis of compounds having a vicinal amino alcohol moiety, such as biologically active compounds.Type: ApplicationFiled: June 20, 2011Publication date: October 17, 2013Applicant: INDUSTRIAL RESEARCH LIMITEDInventors: Simon Peter Harold Mee, Andreas Luxenburger, Lawrence Daniel Harris
-
Publication number: 20130203707Abstract: Novel oxidized lipids are provided herein, as well as methods for producing same, and uses thereof in treating or preventing an inflammation associated with endogenous oxidized lipids and related conditions.Type: ApplicationFiled: March 14, 2013Publication date: August 8, 2013Applicant: Vascular Biogenics Ltd.Inventor: Vascular Biogenics Ltd.
-
Publication number: 20130137861Abstract: A reagent for oligonucleotide synthesis or purification, wherein the reagent has a structure of: X—C-L-H??(Formula A) wherein X is a phosphoramidite group, an H-phosphonate group, an acetal group, or an isocyanate; C is a direct bond or a cleavable adaptor represented by —Ca-Cb—; L is a hydrocarbyl chain; and H is a terminal alkyne or an activated cyclooctyne. The reagent of Formula (A) can be used in the synthesis and purification of oligonucleotides.Type: ApplicationFiled: November 6, 2012Publication date: May 30, 2013Applicant: AGILENT TECHNOLOGIES, INC.Inventor: Agilent Technologies, Inc.
-
Publication number: 20130059970Abstract: Monomers of formula (I) which include a vinyl group, polymers and articles, such as contact lenses, made therefrom, all of which are biocompatible, are described.Type: ApplicationFiled: August 31, 2012Publication date: March 7, 2013Inventors: Michael DRIVER, Brian TARBIT, Alexander GEHRE
-
Publication number: 20130047887Abstract: The present invention describes dental adhesive compositions used for bonding dental biomaterials to hard tissue comprising a polymerizable blend of one or more newly synthesized low shrinkage, stable, multifunctional compounds, where the compounds are acidic-methacrylate derivatives, having excellent properties of bonding the hard tooth substance (enamel or dentin) to dental restorative materials, and present high quality marginal sealing between the tooth and the material thus bond and improved storage stabilityType: ApplicationFiled: October 1, 2010Publication date: February 28, 2013Applicant: SEPTODONT, CONFI-DENTAL DIVISIONInventors: Marianela Trujillo-Lemon, Kristina L. Esquibel, Amy J. Docktor, Zachary R. Shelton, Jeffrey M. Leadford, Kathryn T. Ida, Cora Bracho-Troconis
-
Publication number: 20120329757Abstract: Novel synthetic forms of etherified oxidized phospholipids and methods of utilizing same for preventing and treating atherosclerosis and other related disorders, as well as inflammatory disorders, immune mediated diseases, autoimmune diseases and proliferative disorders, are provided. In addition, methods of synthesizing etherified and esterified oxidized phospholipids and of using same for preventing and treating atherosclerosis and other related disorders are also provided.Type: ApplicationFiled: March 27, 2012Publication date: December 27, 2012Inventors: Dror HARATS, Jacob George, Gideon Halperin, Niva Yacov, Eti Kovalevski-Ishai
-
Publication number: 20120215006Abstract: The present invention relates to a process for the preparation of phosphoric esters, and to selected compounds.Type: ApplicationFiled: October 8, 2010Publication date: August 23, 2012Applicant: MERCK PATENTS GESSELLSCHAFT MIT BESCHRANKTER HAFTUNGInventor: Karl Heinz Gluesenkamp
-
Patent number: 8198474Abstract: The present invention provides methods for preparing TLR-4 receptor agonist E6020: and stereoisomers thereof, which compounds are useful as an immunological adjuvants when co-administered with antigens such as vaccines for bacterial and viral diseases. Also provided are synthetic intermediates useful for implementing the inventive methods.Type: GrantFiled: February 2, 2010Date of Patent: June 12, 2012Assignee: Eisai R&D Management Co., Ltd.Inventors: Francis G. Fang, James E. Foy, Lynn Hawkins, Charles Lemelin, Andre Lescarbeau, Xiang Niu, Kuo-Ming Wu
-
Publication number: 20110319366Abstract: Compounds of the following formula (I), for example: wherein R1, R2, R3, and R4 are described herein, are useful as inhibitors of plasma carboxypeptidase B. Pharmaceutical compositions containing these compounds, methods of using these compounds as antithrombotic agents and processes for synthesizing these compounds are also described herein.Type: ApplicationFiled: August 29, 2011Publication date: December 29, 2011Inventors: Brad Buckman, Kumar Emayan, Imadul Islam, Karen May, Judi Bryant, Raju Mohan, Christopher West, Shendong Yuan
-
Publication number: 20110236931Abstract: Provided is a method to identify OP-adducted biomarkers of OP exposure as well as compounds containing OPs that can provide OP adducts.Type: ApplicationFiled: April 14, 2009Publication date: September 29, 2011Applicant: HUMAN BIOMOLECULAR RESEARCH INSTITUTEInventors: John R. Cashman, Mary T. MacDonald
-
Publication number: 20110207703Abstract: Novel oxidized lipids are provided herein, as well as methods for producing same, and uses thereof in treating or preventing an inflammation associated with endogenous oxidized lipids and related conditions.Type: ApplicationFiled: November 5, 2009Publication date: August 25, 2011Applicant: Vascular Biogenics Ltd.Inventors: Eti Kovalevski-Ishai, Zeev Ziniuk, Gideon Halperin, Itzhak Mendel, Erez Feige, Niva Yacov, Eyal Breitbart
-
Publication number: 20110136735Abstract: The present invention provides a compound of formula I; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.Type: ApplicationFiled: November 30, 2010Publication date: June 9, 2011Inventors: David BARNES, Gregory Raymond BEBERNITZ, Scott Louis COHEN, Robert Edson DAMON, Robert Francis DAY, Monish JAIN, Rajeshri Ganesh KARKI, Louise Clare KIRMAN, Tajesh Jayprakash PATEL, Brian Kenneth RAYMER, Herbert Franz SCHUSTER, Wei ZHANG
-
Publication number: 20110124601Abstract: The present invention relates to a compound of the following general formula (I): R1—NH—CH(R2)—P(?O)(OR3)—CH2—C(R4)(R5)—CONH—CH(R6)—COOR7 (I) or a pharmaceutically acceptable salt of the latter, an isomer or a mixture of isomers in any proportions, especially a mixture of enantiomers, and in particular a racemic mixture, for which R1 represents a —C(?O)—O—C(R8)(R9)—OC(?O)—R10 group; R2 represents an optionally substituted hydrocarbon-based chain, an aryl or heteroaryl group or a methylene group substituted by a heterocycle; R3 represents a hydrogen atom or a —C(R12)(R13)—OC(?O)—R14 group; R4 and R5 form, together with the carbon that bears them, a saturated hydrocarbon-based ring or an optionally substituted piperidine ring or R4 represents a hydrogen atom and R5 represents a phenyl or a benzyl that is optionally substituted, a heteroaromatic ring or a methylene group substituted by a heterocycle; R6 represents an optionally substituted hydrocarbon-based chain or a phenyl or a benzyl that is optionally substiType: ApplicationFiled: July 22, 2009Publication date: May 26, 2011Inventors: Bernard Roques, Hervé Poras, Marie-Claude Fournie-Zaluski
-
Publication number: 20110097350Abstract: Novel synthetic forms of etherified oxidized phospholipids and methods of utilizing same for preventing and treating atherosclerosis and other related disorders, as well as inflammatory disorders, immune mediated diseases, autoimmune diseases and proliferative disorders, are provided. In addition, methods of synthesizing etherified and esterified oxidized phospholipids and of using same for preventing and treating atherosclerosis and other related disorders are also provided.Type: ApplicationFiled: January 6, 2011Publication date: April 28, 2011Applicant: Vascular Biogenics Ltd.Inventors: Dror HARATS, Jacob George, Gideon Halperin, Niva Yacov, Eti Kovalevski-Ishai
-
Patent number: 7906674Abstract: The invention relates to oxidized phospholipids having one of the general formulas (I) or (II) wherein A?O, C, NH, or S; B?O, C, NH, or S; and R2 is selected from the group consisting of —CO—(CH2)n—CH3; —CO—(CH2)n—CHO; and —CO—(CH2)n—COOH, with n=3-7, with the proviso that in general formula (I), R1 is selected from the group consisting of —CH2—(CH2)n—X; and —CO—(CH2)n—X with n=5-11, wherein X is a fluorophore; and in general formula (II), R1 is selected from the group consisting of —CH?CH—(CH2)n—CH3 with n=9-15; —(CH2)n—CH3 with n=11-17; and —CO—(CH2)n—CH3 with n=10—16; and R3 is selected from the group consisting of —CO—(CH2)n—X; and —SO2—(CH2)n—X, with n=0-5, wherein X is a fluorophore.Type: GrantFiled: July 26, 2006Date of Patent: March 15, 2011Inventors: Albin Hermetter, Michael Trenker
-
Patent number: 7902176Abstract: Novel synthetic oxidized lipids and methods utilizing oxidized lipids for treating and preventing an inflammation associated with an endogenous oxidized lipid are provided.Type: GrantFiled: May 27, 2004Date of Patent: March 8, 2011Assignee: Vascular Biogenics Ltd.Inventors: Dror Harats, Jacob George, Gideon Halperin, Niva Yacov, Eti Kovalevski-Ishai
-
Publication number: 20110040053Abstract: A polysiloxane includes a structural unit in which a functional group represented by a general formula of (in the formula, each of R1, R2, and R3 is independently an alkyl group with a carbon number of 1 or more and 6 or less and m is an integer of 2 or more and 6 or less), an ester bond or an amide bond, a spacer, and a silicon atom are bonded sequentially.Type: ApplicationFiled: March 31, 2009Publication date: February 17, 2011Applicant: SHISEIDO COMPANY, LTD.Inventors: Yukimitsu Suda, Kazuyuki Miyazawa
-
Publication number: 20100303804Abstract: The present invention relates to a polymerization-curable composition for the preparation of biodegradable, biocompatible, cross-linked polymers on the basis of polyvinyl alcohol comprising: 5 to 100% by weight of (a) vinyl ester monomer(s) of one of the general formulas (I) to (III): wherein X is oxygen, sulfur, nitrogen, or phosphorus; n is 1 to 1000, at least 20% of the n being ?2; the R1 are selected from hydrogen; straight, branched or cyclic, saturated or unsaturated, n-valent hydrocarbon groups having 1 to 30 carbon atoms, which optionally have heteroatoms and are optionally substituted with one or more substituents selected from —OH, —COON, —CN, —CHO, and ?O, and n-valent radicals of biodegradable, biocompatible oligomers and polymers; m is an integer from 1 to 5; the R2 are selected from hydrogen, —OH, ?O, and the options listed for R1; and the R3 are selected from hydrogen, —OH, and the options listed for R1; 0 to 50% by weight of ethylenically unsaturated co-monomers; 0 to 10% by weight of (a)Type: ApplicationFiled: November 21, 2008Publication date: December 2, 2010Applicant: TECHNISCHE UNIVERSITAT WIENInventors: Robert Liska, Jürgen Stampfl, Franz Varga, Heinrich Gruber, Stefan Baudis, Christian Heller, Monika Schuster, Helga Bergmeister, Günter Weigel, Claudia Dworak
-
Publication number: 20100197951Abstract: The present invention provides methods for preparing TLR-4 receptor agonist E6020: and stereoisomers thereof, which compounds are useful as an immunological adjuvants when co-administered with antigens such as vaccines for bacterial and viral diseases. Also provided are synthetic intermediates useful for implementing the inventive methods.Type: ApplicationFiled: February 2, 2010Publication date: August 5, 2010Applicant: Eisai R & D Management Co., Ltd.Inventors: Francis G. FANG, James E. Foy, Lynn Hawkins, Charles Lemelin, Andre Lescarbeau, Xiang Nu, Kuo-Ming Wu
-
Publication number: 20100184974Abstract: The present invention provides HIV protease inhibitors of formulas I, IA, IB, Ib or II, or pharmaceutically acceptable salts thereof, wherein R2 may be, for example, 2-pyridyl-CH2—, 3-pyridyl-CH2—, 4-pyridyl-CH2—, a sulfonyl group as described in the formulas herein including benzenesulfonyl or thiophenesulfonyl groups, R2a—CO)—, R2a being selected from the group consisting of piperonyl, 2-pyranzinyl (unsubstituted or substituted with H, or an alkyl of 1 to 4 carbon atoms) or a picolylamine group as described herein, wherein R3 may be, for example, a phenyl group or diphenylmethyl group as described herein, and wherein Cx may be, for example, COOH, CONR5R6, CH2OH or CH2OR7.Type: ApplicationFiled: September 20, 2007Publication date: July 22, 2010Applicant: Ambrilia Biopharma Inc.Inventors: Brent Richard Stranix, Jean-Francois Lavallee, Nicolas LeBerre, Valerie Perron, Dominik Herbart, Guy Milot, Chandra Panchal
-
Publication number: 20100137258Abstract: The invention relates to thiophosphi(o)nic acid derivatives having formula (I) wherein. M is a [C(R3,R4)]n1-C(E,COOR1,N(H,Z)) group, or an optionally substituted Ar—CH(COOR1,N(H,Z)) group (Ar designating an aryl or an heteroaryl group), or an ?, ? cyclic aminoacid group such as, formula (II) or a ?, &ggr;-cyclic aminoacid group such as, formula (III).Type: ApplicationFiled: August 1, 2008Publication date: June 3, 2010Inventors: Francine Acher, Chelliah Selvam, Jean-Philippe Pin
-
Patent number: 7683200Abstract: The present invention provides methods for preparing TLR-4 receptor agonist E6020: and stereoisomers thereof, which compounds are useful as an immunological adjuvants when co-administered with antigens such as vaccines for bacterial and viral diseases. Also provided are synthetic intermediates.Type: GrantFiled: June 30, 2006Date of Patent: March 23, 2010Assignee: Eisai R & D Management Co., Ltd.Inventors: Francis G. Fang, James E. Foy, Lynn Hawkins, Charles Lemelin, Andre Lescarbeau, Xiang Nu, Kuo-Ming Wu
-
Publication number: 20100029903Abstract: The invention provides novel compounds comprising a protracting tag linked to therapeutically active compounds.Type: ApplicationFiled: December 13, 2006Publication date: February 4, 2010Applicant: Novo Nordisk A/SInventors: Kilian Waldemar Conde Frieboes, Florencio Zaragoza Dorwald, Janos Tibor Kodra
-
Patent number: 7625882Abstract: Novel synthetic oxidized lipids and methods utilizing oxidized lipids for treating and preventing an inflammation associated with an endogenous oxidized lipid are provided.Type: GrantFiled: September 28, 2006Date of Patent: December 1, 2009Assignee: Vascular Biogenics Ltd.Inventors: Dror Harats, Jacob George, Gideon Halperin, Itzhak Mendel
-
Publication number: 20090163725Abstract: A phosphonic acid diester derivative represented by the following general formula (1): wherein at least one of R1 and R2 denotes a leaving group.Type: ApplicationFiled: November 30, 2006Publication date: June 25, 2009Inventors: Jun Hiratake, Kanzo Sakata, Liyou Han
-
Publication number: 20090130648Abstract: The invention relates to oxidized phospholipids having one of the general formulas (I) or (II) wherein A=O, C, NH, or S; B?O, C, NH, or S; and R2 is selected from the group consisting of —CO—(CH2)n—CH3; —CO—(CH2)b—CHO; and —CO—(CH2)n—COOH, with n=3-7, with the proviso that in general formula (I), R1 is selected from the group consisting of —CH2—(CH2)n—X; a —CO—(CH2)n—X with n=5-11, wherein X is a fluorophore; and in general formula (II), R1 is selected from the group consisting of —CH?CH—(CH2)n—CH3 with n=9-15; —(CH2)n—CH3 with n=11-17; and —CO—(CH2)n—CH3 with n=10-16; and R3 is selected from the group consisting of —CO—(CH2)n—X; and —SO2—(CH2)n—X, with n=0-5, wherein X is a fluorophore.Type: ApplicationFiled: July 26, 2006Publication date: May 21, 2009Applicants: TECHNISCHE UNIVERSITÄT GRAZ, FORSCHUNGSHOLDING TU GRAZ GMBHInventors: Albin Hermetter, Michael Trenker
-
Publication number: 20090131373Abstract: The present invention relates to novel phospholipids complexes of curcumin or extracts containing it having improved bioavailability.Type: ApplicationFiled: February 21, 2007Publication date: May 21, 2009Inventors: Andrea Giori, Federico Franceschi
-
Patent number: 7527733Abstract: The present invention provides for Troika acids attached to a macroporous resin and Methods of preparing the same, including direct attachment of a Troika acid, and attachment of a Troika acid precursor followed by generation of the Troika acid in situ. Methods of functionalizing a resin to facilitate attachment are also described. Multiple Troika acids, comprising a pair of Troika acids joined together are described. Synthetic routes to both microporous and macroporous resins modified by introduction of a suitable Troika-type acid have been designed and validated. In a preferred embodiment, a macroporous Troika resin removes Cu2+ and Ni2+ from aqueous solution with high affinity, and is selective against Mg2+ or Ca2+. The materials of the present invention have advantages for metal removal from power plant waste water.Type: GrantFiled: September 30, 2004Date of Patent: May 5, 2009Assignee: The University of Southern CaliforniaInventors: Charles E. McKenna, Boris A Kashemirov, Isabelle Favier, Thomas D. Wolfe
-
Patent number: 7504388Abstract: Novel synthetic forms of etherified oxidized phospholipids and methods of utilizing same for preventing and treating atherosclerosis and other related disorders, as well as inflammatory disorders, immune mediated diseases, autoimmune diseases and proliferative disorders, are provided. In addition, methods of synthesizing etherified and esterified oxidized phospholipids and of using same for preventing and treating atherosclerosis and other related disorders are also provided.Type: GrantFiled: July 19, 2005Date of Patent: March 17, 2009Assignee: Vascular Biogenics Ltd.Inventors: Dror Harats, Jacob George, Gideon Halperin, Niva Yacov, Eti Kovalevski-Ishai
-
Publication number: 20090042840Abstract: A phospholipid comprising a diacyl-substituted phosphatidyl group and a pharmaceutical composition comprising such a phospholipid for use in treatment of an allergic inflammatory condition and a method for the treatment of an allergic inflammatory condition. The phospholipid is particularly a mixture of phospholipids known as pumactant.Type: ApplicationFiled: May 23, 2006Publication date: February 12, 2009Inventors: Derek Alan Woodcock, Christopher Pynn, Anthony Postle
-
Publication number: 20080312191Abstract: The present invention relates to novel compounds with inhibitory activity towards urokinase plasminogen activator (uPA); to methods for preparation of said uPA inhibitor compounds; to pharmaceutical compositions comprising said uPA inhibitor compounds; to the use of said uPA inhibitor compounds as a medicament and the use of said uPA inhibitor compounds for the preparation of a medicament for the treatment of conditions chosen from the group comprising cancer, tumour growth, tumour invasion, tumour metastasis, diabetic retinopathy, hemorrhagic atherosclerosis and inflammatory conditions, such as rheumatoid arthritis and psoriasis.Type: ApplicationFiled: October 20, 2006Publication date: December 18, 2008Applicant: UNIVERSITEIT ANTWERPENInventors: Koen Augustyns, Jurgen Joossens, Pieter Van Der Veken, Anne-Marie Virginie Renee Lambeir, Simon Scharpe, Achiel Haemers
-
Publication number: 20080194843Abstract: Crosslinkers having a covalently bonded phosphorous atom, the phosphorous atom having at least one covalently bonded oxygen atom. Crosslinkers can be used with resins such as epoxy, acrylic, polyurethane, polycarbonate, polysiloxane, polyvinyl, polyether, aminoplast, and polyester resins. A process to produce a crosslinker includes incorporating a pendent group comprising a covalently bonded phosphorous atom.Type: ApplicationFiled: February 8, 2007Publication date: August 14, 2008Applicant: BASF CORPORATIONInventors: Sergio GONZALEZ, Timothy S. December
-
Patent number: 7408075Abstract: Aspects of the present invention include methods of synthesizing phosphocholine analogues and the phosphocholine conjugates formed therefrom and their use in preventing infections caused by microorganisms.Type: GrantFiled: March 21, 2006Date of Patent: August 5, 2008Assignee: The United States of America as represented by the Department of Health and Human ServicesInventor: Louis J Rezanka
-
Patent number: 7354895Abstract: The present invention relates to compounds of Formula I, and pharmaceutically acceptable salts or solvates thereof, or solvates of such salts, which compounds inhibit carboxypeptidase U and thus can be used in the prevention and treatment of diseases associated with carboxypeptidase U. In further aspects, the invention relates to compounds of the invention for use in therapy; to processes for preparation of such new compounds; to pharmaceutical compositions containing at least one compound of the invention, or a pharmaceutically acceptable salt or solvate thereof, as active ingredient; and to the use of the active compounds in the manufacture of medicaments for the medical use indicated above.Type: GrantFiled: May 3, 2000Date of Patent: April 8, 2008Assignee: AstraZeneca ABInventors: Marcel Linschoten, Magnus Polla
-
Patent number: 7326801Abstract: Compounds of formula I wherein m, R, R1 and R3 to R6 are as defined in the specification, m, is 1, 2 or 3 and X is O or a direct bond, and the corresponding unphosporylated compounds have interesting properties, e.g. immunosuppressive properties.Type: GrantFiled: March 26, 2002Date of Patent: February 5, 2008Assignee: Novartis AGInventors: Rainer Albert, Thomas Baumruker, Volker Brinkmann, Sylvain Cottens, Klaus Hinterding, Christos Papageorgiou, Eva Erika Prieschl-Strassmayr
-
Patent number: 7186704Abstract: Novel synthetic forms of etherified oxidized phospholipids and methods of utilizing same for preventing and treating atherosclerosis and other related disorders, as well as inflammatory disorders, immune mediated diseases, autoimmune diseases and proliferative disorders, are provided. In addition, methods of synthesizing etherified and esterified oxidized phospholipids and of using same for preventing and treating atherosclerosis and other related disorders are also provided.Type: GrantFiled: November 24, 2003Date of Patent: March 6, 2007Assignee: Vascular Biogenics Ltd.Inventors: Dror Harats, Jacob George, Gideon Halperin
-
Patent number: 7141557Abstract: A method of treating viral infections, and in particular HIV-1, hepatitis B virus, and herpes virus, is disclosed. The method comprises administering to a subject in need of such treatment an infection-controlling amount of a phospholipid or phospholipid derivative.Type: GrantFiled: September 20, 2004Date of Patent: November 28, 2006Assignees: Wake Forest University, University of North Carolina at Chapel HillInventors: Louis S. Kucera, Susan L. Morris-Natschke, Khalid S. Ishaq